TY - JOUR
T1 - Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata
AU - Sanchis, Marta
AU - Capilla, Javier
AU - Castanheira, Mariana
AU - Martin-Vicente, Adela
AU - Sutton, Deanna A.
AU - Fothergill, Annette W.
AU - Wiederhold, Nathan P.
AU - Guarro, Josep
N1 - Funding Information:
Funding : This project has been partially funded by the European Union's Seventh Framework Programme for Research, Technological Development and Demonstration [grant agreement no. HEALTH-2013-INNOVATION-2-601963 ].
Publisher Copyright:
© 2016 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
PY - 2016/4
Y1 - 2016/4
N2 - In this study, 27 clinical isolates of Candida glabrata with voriconazole (VRC) minimum inhibitory concentrations (MICs) ranging from ≤0.03 μg/mL to 8 μg/mL were tested to determine whether in vitro data are predictive of in vivo efficacy. The efficacy of VRC administered at 40 mg/kg was assayed in a neutropenic murine model of disseminated infection by C. glabrata. The reduction in fungal tissue burden in the kidneys was used as a marker of treatment efficacy. VRC reduced the fungal tissue burden in mice infected with strains that had MICs below the epidemiological cut-off value (ECV) of 0.25 μg/mL. Variable efficacy of VRC was obtained when the MIC equalled the ECV, and VRC was ineffective when the MIC exceeded the ECV. These results suggest that the use of in vitro data could be useful to predict the outcome for infections by this fungus.
AB - In this study, 27 clinical isolates of Candida glabrata with voriconazole (VRC) minimum inhibitory concentrations (MICs) ranging from ≤0.03 μg/mL to 8 μg/mL were tested to determine whether in vitro data are predictive of in vivo efficacy. The efficacy of VRC administered at 40 mg/kg was assayed in a neutropenic murine model of disseminated infection by C. glabrata. The reduction in fungal tissue burden in the kidneys was used as a marker of treatment efficacy. VRC reduced the fungal tissue burden in mice infected with strains that had MICs below the epidemiological cut-off value (ECV) of 0.25 μg/mL. Variable efficacy of VRC was obtained when the MIC equalled the ECV, and VRC was ineffective when the MIC exceeded the ECV. These results suggest that the use of in vitro data could be useful to predict the outcome for infections by this fungus.
KW - Animal model
KW - Antifungals
KW - Candida glabrata
KW - Epidemiological cut-off value
KW - Fungal infection
KW - Voriconazole
UR - http://www.scopus.com/inward/record.url?scp=84960145780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960145780&partnerID=8YFLogxK
U2 - 10.1016/j.ijantimicag.2015.12.020
DO - 10.1016/j.ijantimicag.2015.12.020
M3 - Article
C2 - 26976780
AN - SCOPUS:84960145780
SN - 0924-8579
VL - 47
SP - 286
EP - 288
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
IS - 4
ER -